Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis

INTRODUCTION

Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disorder of the central nervous system (CNS). Two major forms of MS have been recognized: sporadic (sMS) and familial (fMS). In fMS apart from an index case at least one more family member should be diagnosed with MS,[1]. It is estimated that fMS affects about 12.6 - 20% of all patients with MS (pwMS),[2-4]. The genetics of MS is complex and correspond to polygenic trait. It is believed that MS genetics can explain up to half of the disease’s heritability,[5, 6]. Classical twin studies showed that unaffected monozygotic twin have much higher risk to develop MS, 25-30%, than dizygotic twin, 2-5%,[7, 8]. The average risk of developing MS by relatives of pwMS ranged from 3 to 5%, with the highest risk for first-degree relatives, and was 30 to 50 times higher than the 0,1% risk for the general population,[2]. These data suggest that fMS might represent a more genetically driven form of MS versus sMS. Clinical phenotyping of these two forms of MS did not reveal any major differences,[9-11]. However, some discordance was observed. It was found that pwMS with multiple affected relatives had a higher incidence of optic neuritis (ON) as the first relapse, a lower risk of another relapse in the first year of disease, a longer interval between the first and second relapse, and a longer time to permanent neurological deficit,[3]. Also MRI studies have shown some differences between these two forms of MS. In fMS compared to sMS was observed a larger T1-lesion volume and a trend toward lower MTR of T1-lesions,[12]. Our own earlier studies showed that MTR abnormalities were more widespread in fMS than in sMS. MTR values were reduced mainly in the corpus callosum and in the cerebral and cerebellar peduncles, primarily involving areas of highly myelinated white matter,[13]. Proton magnetic resonance spectroscopy showed a slight decrease in NAA/Cho and NAA/Cr ratios in normal appearing white matter in sMS versus fMS, whereas Cho/Cr ratio showed an increased trend. These results might indicate more pronounced neurodegenerative injury in sMS than in fMS,[14].

To address this hypothesis, we applied optic coherence tomography (OCT) technique and aimed to study axonal and neuronal damage of the retina in patients with sMS and fMS. OCT is a non-invasive interferometric technique, allowing for assessment of axonal and neuronal damage by measurement of retinal nerve fibre layer (RNFL) thickness and macular volume (MV). The RNFL is formed by unmyelinated retinal ganglion cell axons, whereas ganglion cell neurons are a major component of the macula,[15, 16]. Several studies reported a positive correlation of the RNFL thinning with brain atrophy in MS, which suggested that RNFL thickness might be an indirect marker of diffuse axonal damage in the brain,[17-19]. The reduction of MV in MS was associated with neurodegenerative neuronal changes. Hence, MV might represent a quantitative marker of neuronal damage in the brain,[20-22].

We analysed RNFL thickness and MV in a cohort of patients with fMS and sMS and healthy volunteers and investigated how ON affected the OCT parameters in patients with both forms of MS.

METHODS

RESULTS

DISCUSSION

We have found that RNFL thickness and MV in sMS and fMS were significantly diminished in comparison to control subjects. These findings confirmed the presence of axonal and neuronal damage of the retina in patients with sMS and fMS. The global and segmental thickness of RFNL and MV were similar in both sMS and fMS. However, we have found that the impact of previous optic neuritis on MV was bigger in sMS than in fMS, suggesting more pronounced neuronal damage of the retina in sMS.

OCT offers non-invasive and relatively simple method to assess axonal and neuronal changes of the retina. RNFL measures axonal thickness of ganglion cells and MV corresponds to the count of two or more layers of ganglion cells,[16, 17, 25]. Over the last several years numerous studies demonstrated diminished RNFL in pwMS,[26-28]. Most importantly, RFNL thickness correlated to diffuse axonal changes throughout the CNS of pwMS,[18,19]. In particular RNFL correlated with global and regional brain atrophy,[18-22], with MRI lesion load,[18, 29], MTR measures,[30], with NAA/Cho ratio in proton brain MRI spectroscopy,[31], as well as with cerebrospinal fluid neurofilament light chain levels,[32]. On the other hand measurements of MV and ganglion cell-inner plexiform layer (GCIPL) thickness were suggested to be more reliable at detecting neuronal degenerative processes in MS,[26, 28]. Similarly to RNFL thinning in pwMS reduction of MV and GCIPL thickness correlated with brain pathology and enhanced brain atrophy,[20,22].

The unique ability to monitor axonal and neuronal injury in vivo using OCT contributed to better understanding of global pathological processes in MS. The reported correlation of RNFL thickness and MV with MRI parameters, particularly with markers of brain atrophy in pwMS, makes OCT a useful method for monitoring neurodegenerative changes in this disease,[19, 22]. The findings that ON induced a larger reduction of MV in patients with sMS should be interpreted from the mechanistic point of view how ON affects the retinal pathology. Changes in the retina caused by inflammation in the optic nerve in the classical interpretation represents a consequence of its demyelination, leading to retrograde axonopathy as thinning of RNFL. This pattern of RNFL changes we observed in both sMS and fMS. However, in sMS ON induced significantly greater reduction of MV than in fMS and in this latter form reduction of MV was quite limited. Since MV corresponds to number of neuronal ganglion cells and it is recognized as a marker for neuronal cell pathology,[20-22, 34] one might suggest that ON in sMS has a particular impact on neuronal damage of the retina. This observation might be of interest from the perspective of the role of primary neuronal damage in the CNS of pwMS. It has been suggested that MS pathology apart from demyelination and secondary axonopathy also involves neuronal damage,[35, 36]. Its relationship to inflammation is still under discussion. Differences in the degree of neuronal damage in the retina after ON between sMS and fMS might suggest discordance in inflammation-induced tissue damage in these two forms of MS. Whether this would be related to specific genetic background in sMS and fMS remains for further investigations. Nevertheless these results might indicate that retinal changes in pwMS might have more complex pattern influenced by genetic trait.

There is still ongoing discussion on the distinction between familial and sporadic forms of MS. The major issue is how much these two forms might differ in terms of genetic background leading to some differences in pathologic mechanisms. The attempt to characterize fMS by genetic screening is not available yet. However, in that context, of interest might be results of studies on MRI findings in asymptomatic relatives of patients with sMS and fMS. The 11% of asymptomatic siblings of MS patients showed demyelinating brain lesions similar to that seen in MS,[37]. Our own earlier study with MTR assessment of normal appearing white matter reported diminished MTR histogram peak heights in asymptomatic relatives of MS patients,[38]. Similarly a study with proton magnetic resonance spectroscopy showed lower NAA/Cho and higher Cho/Cr ratio in asymptomatic relatives of pwMS,[15]. In the large cohort of first degree asymptomatic relatives of sMS and fMS patients a higher prevalence of MRI lesions was found in fMS, 10% compared with 4% in sMS,[39]. The demonstrated differences in brain imaging in relatives of patients with fMS and sMS may perhaps support the existence of some genetic differences between these two forms of MS.

Our results have some obvious limitations related to the definition of fMS. However, the cohort of pwMS used in this study was derived from prospective analysis reducing biases related to the development of new cases in relatives over time. In addition the mean age of pwMS in this study, 39,86 for fMS and 38,28 years for sMS, was clearly above pooled mean age of fMS onset of 15 studies reported as 28,7Lyears,[40]. Also, the affected members of the family were carefully evaluated with medical records and neurological examinations.

In conclusion, our findings on a different impact of ON on MV in sMS and fMS and more pronounced neuronal injury of the retina in sMS patients might support discrete differences in pathologic mechanisms between sMS and fMS.

Funding

This study was supported by a grant PRELUDIUM from the National Science Center, Cracow, Poland, grant number UMO-2014/15/N/NZ4/01704

Competing interests

MGP has nothing to report. KS has received personal compensation for consulting from Biogen, Celgene, GeNeuro, Merck, Novartis, Polpharma, Sanofi, Roche, TG Therapeutics, and received research support from Merck and Roche.

Contributors

MGP contributed to data collection, analysed imaging, designed and conceptualised the study, analysed and interpreted all data, and drafted the manuscript. KS designed and conceptualised the study, analysed and interpreted all data, drafted, revised the manuscript. KS was the guarantor for this study.

The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted

Copyright/licence for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Patient consent for publication

Not applicable.

Ethics approval

The study was approved by Ethical Commission of the Medical University of Lodz, Poland (registration numbers: RNN/83/13/KE, RNN/178/16/KE).

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data are available upon reasonable request.